A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/04/2004	US20040220147 Antiarrhythmia agents; liver disorders; skin disorders
11/04/2004	US20040220146 Methods and compositions for treating fungal infections
11/04/2004	US20040220145 Methods for treating hearing loss
11/04/2004	US20040220144 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
11/04/2004	US20040220143 Oral delivery of macromolecules
11/04/2004	US20040220141 Method for producing purified hematinic iron-saccharidic complex and product produced
11/04/2004	US20040220140 poly n-acetylglucosamine and stored platelets; wound healing agents
11/04/2004	US20040220139 viricide; interference with binding of viruses to cells; utilization pH variations
11/04/2004	US20040220138 Methods for modulating neuronal cell death
11/04/2004	US20040220136 bioavailability of cobalamin; mixture with cytokine; controlling gene expression of protein
11/04/2004	US20040220135 synergistic mixtures of fluorouracil and folinic acid; anticancer agents; antitumor agents
11/04/2004	US20040220134 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
11/04/2004	US20040220133 Composition and method for inhibiting platelet aggregation
11/04/2004	US20040220132 Treatment of neurodegenerative disease through intracranial delivery of siRNA
11/04/2004	US20040220122 Administering teichoplanin; remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection
11/04/2004	US20040220121 Methods for drug delivery
11/04/2004	US20040220120 mixture of lactone and carrier;
11/04/2004	US20040220119 flavonoids for therapy, prevention skin disorders; topical administering
11/04/2004	US20040220117 Proteotoxin neutralizer
11/04/2004	US20040220116 mixture with polysorbate; beverages, cosmetics, nutrient adjuvants, cleaning compounds,
11/04/2004	US20040220115 prevent interaction of target cell with glycoalkaloid ; anticancer agents; contraceptives
11/04/2004	US20040220114 Pharmaceutical compositions and treatment methods
11/04/2004	US20040220113 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions
11/04/2004	US20040220112 administering 2-(N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide as an anti-pruritic agent; antihyperalgesics; analgesics; central nervous system side effect reduction
11/04/2004	US20040220109 controlling dietetic fats and,or antilipemic agents ; reducing blood lipid concentration
11/04/2004	US20040220090 Advanced glycation end-product intermediaries and post-amadori inhibition
11/04/2004	US20040220086 contacting with protein which binds to cells in diseased tissue; antitumor agents
11/04/2004	US20040220083 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body
11/04/2004	US20040220081 Nanoparticulate bioactive agents
11/04/2004	US20040220079 Inhibitors of Memapsin 2 and use thereof
11/04/2004	US20040220078 Aqueous solution of oxaliplatinum in glass flask
11/04/2004	US20040220077 Therapy for neuropathic pain
11/04/2004	US20040220076 Prevention of recurrent viral disease
11/04/2004	US20040220075 Treatment of skin disorders
11/04/2004	US20040220055 Benzamidoacetonitriles and their use as antiparastics
11/04/2004	US20040219648 growing microflora in fermentation medium containing sodium sulfate; extraction; aquaculture; for use in flaxseed, rapeseed, soybean and avocado meal
11/04/2004	US20040219603 Method and kit for detecting the early onset of renal tubular cell injury
11/04/2004	US20040219575 Using presence of transcription factor/tumor antigen splice variant to diagnose cell proliferative disorders; tumor cell characterization
11/04/2004	US20040219552 Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening; kits
11/04/2004	US20040219262 Food and vitamin preparations containing the natural isomer of reduced folates
11/04/2004	US20040219240 hops extracts or derivatives, in combination with an analgesic compound and/or an anti-inflammatory compound for reducing gastroenteropathy or gastric toxicity, including ulcerogenic-type disorders
11/04/2004	US20040219239 Nutritional supplement based on blackcurrent seed oil
11/04/2004	US20040219238 Prophylactic agent for enhancement of nerve growth factor production for treatment or prevention comprising an aqueous mushroom extract (xanthohumol or salts) ; neurodegenerative diseases, Alzheimer*s disease, and nervoxanthohumol andus system disorders; foods, beverages, feeds;
11/04/2004	US20040219230 Compositions for preparing external carbon dioxide agents
11/04/2004	US20040219229 Migraine relief composition and methods of using and forming same
11/04/2004	US20040219227 synergistic mixture of octoxyglycerin, a quaternary ammonium compound, an antimicrobial agent, and a zinc compound; enhanced rapid and long-term antimicrobial efficacy
11/04/2004	US20040219220 Therapeutic agents
11/04/2004	US20040219219 Compositions containing alpha-2-adrenergic agonist components
11/04/2004	US20040219218 tablets or capsules of T3 or T4 or their salts in a uniform soft gel matrix that can be taken orally without chewing
11/04/2004	US20040219213 Oral pulsed dose drug delivery system
11/04/2004	US20040219212 Single-daily dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/04/2004	US20040219211 a tablet which disintigrates in the mouth, having enterically coated microgranules of a benzimidazole type proton pump inhibitor overcoated with a methacrylic copolymer protective coating, granular antacids, a disintegrating agent, a diluent, and a lubricant; gastrointestinal disorders
11/04/2004	US20040219210 sustained release tablets wtih a rheology modifying crosslinked polymer having acrylic (di)acid, anhydride, or monoesterified diacid monomers and optional acrylic ester or vinyl ether comonomer, an excipient, a surface active agent and a solubility enhancer
11/04/2004	US20040219209 Controlled release metformin compositions
11/04/2004	US20040219208 Sustained-release medicines
11/04/2004	US20040219207 Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
11/04/2004	US20040219204 Method of treating angiogenic tissue growth
11/04/2004	US20040219201 Tempamine compositions and methods of use
11/04/2004	US20040219200 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/04/2004	US20040219199 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/04/2004	US20040219197 topical mixtures of estrogens or progesterones, and drug delivery vehicles comprising alcohols, alcohols-2+ or polyoxyalylene glycols, and permeation enhancer comprising a monoalkyl ether of diethylene glycol
11/04/2004	US20040219196 multilayer patches comprising barrier layers between polymers films having drugs dispersions and drug antagonist layers, wherein the barrier is permeable to solvents and impermeable to diffusion of drugs and drug antagonist in the absence of solvent; protective devices
11/04/2004	US20040219195 multilayer patches comprising barrier layers between polymers films having drugs dispersions and drug antagonist layers, wherein the barrier is permeable to solvents and impermeable to diffusion of drugs and drug antagonist in the absence of solvent; protective devices
11/04/2004	US20040219194 comprising drug impervious coverings, matrices containing aloe vera extracts, 4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate and/or racemic mixtures, release linings, pressure sensitive adhesive and curing agents for the adhesive.
11/04/2004	US20040219191 Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means
11/04/2004	US20040219189 administering excitatory amino acid agonists to poultry; feeds
11/04/2004	US20040219188 Composition and methods for nutritional management of patients with hepatic disease
11/04/2004	US20040219187 biodegradable prosthetics having coatings selected from retinol, retinal, retinoic acid or p-[(E)-2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyll-2-naphthyl)propenyl]-benzoic acid, used as grafts for eye tissues
11/04/2004	US20040219186 time release agents comprising gel formed from polysaccharides, excipients and drugs
11/04/2004	US20040219177 Depleted skin barrier replenishing skin creams composition and method of application
11/04/2004	US20040219176 dosage form of a mixture of drugs, foaming agents and gases, having improved pharmacokinetics; drug delivery systems
11/04/2004	US20040219174 Contraception process and administration form for the same
11/04/2004	US20040219165 Streptococcus pneumoniae antigens
11/04/2004	US20040219160 Zwitterionic immunomodulators for the treatment of asthma and allergy
11/04/2004	US20040219158 Cystic fibrosis
11/04/2004	US20040219157 Composition comprising a prebiotic for decreasing inflammatory process and abnormal actibation of non-specific immune parameters
11/04/2004	US20040219153 Synergistic tumorcidal response induced by histamine
11/04/2004	US20040219151 Tetraspan protein and uses thereof
11/04/2004	US20040219147 administering an anti-inflammatory compound, especially an antibody to a complement component or an NSAID, to a subject receiving a stent in connection with percutaneous transluminal coronary angioplasty.
11/04/2004	US20040219145 Compositions and methods to modulate immune and inflammatory responses
11/04/2004	US20040219144 administering an anti-human NGF monoclonal antibody capable of binding hNGF with an affinity in the nanomolar range, and inhibiting the binding of hNGF to human TrkA (hTrkA) in vivo, wherein said antibody has no significant adverse effect on the immune system
11/04/2004	US20040219141 Reducer of blood glucose level increase reducer of body fat accumulation and food material
11/04/2004	US20040219138 synergistic combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and opioids are potent analgesics that elevate the pain threshold in hyperalgesic conditions; compound in which the superoxide dismutase catalyst moiety and the opioid moiety are coupled
11/04/2004	US20040219137 Method for reducing exacerbations associated with COPD
11/04/2004	US20040219132 combining gene therapy with active site-specific chaperones to increases the stability and efficiency of the protein encoded by the recombinant gene that is administered.
11/04/2004	US20040219127 Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof
11/04/2004	US20040219123 recrystallization-resistant; also comprising a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB ranging from 2 to 7; preventing/treating the chronological or actinic skin aging and atrophy of the skin or mucous membranes
11/04/2004	US20040219114 Cream for treatment of skin injured by the sun
11/04/2004	US20040219110 Process for removing calculus deposits from the teeth and suppressing pain
11/04/2004	US20040219107 The applicator assembly includes a sleeve that encases a swab having a portion that contacts a gelled composition; the sleeve is manually severed to expose the applicator and the composition
11/04/2004	US20040219106 Compounds for use as surfactants
11/04/2004	US20040219102 Compositions for drug delivery
11/04/2004	US20040216487 Chemical vapor deposition of dirt repellant crystalline titanium oxide on glass, ceramics or vitroceramics
11/04/2004	DE29825080U1 Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit Pharmaceutical fenofibrate with increased bioavailability
11/04/2004	DE10317389A1 Composition containing phenylbutyrate and aminobenzoic acid, useful for treating tumors, particularly glioblastoma and meningioma, has synergistic inhibitory effect on oncoproteins
11/04/2004	DE10315878A1 Transdermale Verabreichung von (R)-3,3-Diphenylpropylamin-Monoestern Transdermal administration of (R) -3,3-diphenylpropylamine monoesters
11/04/2004	DE10315654A1 8-Nitro-Tryptanthrin und andere Tryptanthrin-Derivate zur Therapie von Erkrankungen, die durch hoch-proliferierende Zellen verursacht werden 8-nitro-tryptanthrine and other tryptanthrine derivatives for the treatment of diseases caused by high-proliferating cells
11/04/2004	CA2746531A1 Non-steroidal anti-inflammatory drug dosing regimen
11/04/2004	CA2714572A1 A method and compound for lowering allergy risk
11/04/2004	CA2708045A1 A pharmaceutical compound

1 ... 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 ... 7860